Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib vs Docetaxel in Stage IV Squamous NSCLC
NCT02450539Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of abemaciclib in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Started Aug 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02450539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450539.